Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inhibition of PDE1 (unknown origin)
Assay data:2 Active, 2 Activity ≤ 1 µM, 3 Tested
SummaryRelated BioAssays by Target
Inhibition of human PDE1C
Assay data:1 Tested
Inhibition of recombinant full length PDE1C in human myocardium stimulated by calmodulin using cGMP as substrate at 1 uM
Inhibition of recombinant full length PDE1C in human myocardium stimulated by calmodulin using cAMP as substrate at 1 uM
Inhibition of recombinant full length PDE1C in human myocardium using cGMP as substrate at 1 uM
Inhibition of recombinant full length PDE1C in human myocardium using cAMP as substrate at 1 uM
Inhibition of PDE1C (unknown origin)
Assay data:3 Active, 3 Activity ≤ 1 µM, 3 Tested
Assay data:3 Active, 2 Activity ≤ 1 µM, 3 Tested
PDE1 Inhibition Assay from US Patent US11634416: "Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines"
Assay data:192 Active, 70 Activity ≤ 1 nM, 192 Activity ≤ 1 µM, 192 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Inhibition Assay from US Patent US11535611: "Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors"
Assay data:85 Active, 70 Activity ≤ 1 µM, 85 Tested
PDE1 Inhibition Assay from US Patent US11491140: "1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors"
Assay data:196 Active, 73 Activity ≤ 1 nM, 196 Activity ≤ 1 µM, 196 Tested
Inhibition of PDE1C (147 to 531 residues) (unknown origin) expressed in Escherichia coli BL21 at 1000 nM [3H]-cGMP as substrate measured for 15 mins by liquid scintillation counter method relative to control
Assay data:4 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of PDE1C (147 to 531 residues) (unknown origin) expressed in Escherichia coli BL21 using [3H]-cGMP as substrate measured for 15 mins by liquid scintillation counter method
Assay data:13 Active, 8 Activity ≤ 1 µM, 14 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of cAMP-specific 3',5'-cyclic phosphodiesterase (unknown origin)
Assay data:2 Active, 1 Activity ≤ 1 µM, 4 Tested
Inhibition of human PDE4 at 10 uM relative to control
Inhibition of PDE4 in human U-937 cells assessed as reduction in cAMP level by LANCE cAMP Assay
Assay data:8 Active, 8 Activity ≤ 1 nM, 8 Activity ≤ 1 µM, 8 Tested
Inhibition of PDE1C2 (147 to 531 residues) (unknown origin) using [3H]-cGMP substrate measured for 15 mins by liquid scintillation counting method
Assay data:2 Active, 2 Activity ≤ 1 µM, 2 Tested
Phosphodiesterase Enzyme Assay from US Patent US11453673: "Substituted [1,2,4]triazolo[4,3-a]pyrazines as phosphodiesterase inhibitors"
Assay data:16 Active, 1 Activity ≤ 1 nM, 16 Activity ≤ 1 µM, 16 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Enzyme Assays from US Patent US11401274: "[1,2,4]Triazolo derivatives as PDE1 inhibitors for the treatment of diabetes"
Assay data:8 Active, 8 Activity ≤ 1 µM, 8 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on